Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

JCL roundtable-Lipoprotein(a): The emerging risk factor.

Marcovina SM, Moriarty PM, Koschinsky ML, Guyton JR.

J Clin Lipidol. 2018 Nov - Dec;12(6):1335-1345. doi: 10.1016/j.jacl.2018.11.003. Review.

PMID:
30527801
2.

Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions.

Goldberg RB, Bray GA, Marcovina SM, Mather KJ, Orchard TJ, Perreault L, Temprosa M; Diabetes Prevention Program Research Group.

Diabetologia. 2019 Jan;62(1):58-69. doi: 10.1007/s00125-018-4748-2. Epub 2018 Oct 17.

PMID:
30334082
3.

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, Reyes-Soffer G.

J Lipid Res. 2018 Dec;59(12):2397-2402. doi: 10.1194/jlr.P082834. Epub 2018 Oct 7.

PMID:
30293969
4.

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.

PMID:
30262460
5.

Inflammation, adiposity, and progression of arterial stiffness in adolescents with type 1 diabetes: The SEARCH CVD Study.

Alman AC, Talton JW, Wadwa RP, Urbina EM, Dolan LM, Hamman RF, D'Agostino RB Jr, Marcovina SM, Dabelea DM.

J Diabetes Complications. 2018 Nov;32(11):995-999. doi: 10.1016/j.jdiacomp.2018.08.004. Epub 2018 Aug 9.

PMID:
30209019
6.

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.

Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM.

J Clin Lipidol. 2018 Sep - Oct;12(5):1313-1323. doi: 10.1016/j.jacl.2018.07.003. Epub 2018 Jul 20.

PMID:
30100157
7.

Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization.

Delatour V, Clouet-Foraison N, Gaie-Levrel F, Marcovina SM, Hoofnagle AN, Kuklenyik Z, Caulfield MP, Otvos JD, Krauss RM, Kulkarni KR, Contois JH, Remaley AT, Vesper HW, Cobbaert CM, Gillery P.

Clin Chem. 2018 Oct;64(10):1485-1495. doi: 10.1373/clinchem.2018.288746. Epub 2018 Aug 7.

PMID:
30087138
8.

Refining Lipoprotein(a) Associated Cardiovascular Risk in Women.

Rosenson RS, Marcovina SM.

J Am Coll Cardiol. 2018 Jul 17;72(3):297-299. doi: 10.1016/j.jacc.2018.05.011. Epub 2018 Jul 9. No abstract available.

PMID:
30012323
9.

Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial.

Toth PP, Jones SR, Slee A, Fleg J, Marcovina SM, Lacy M, McBride R, Boden WE.

J Clin Lipidol. 2018 May - Jun;12(3):741-747.e11. doi: 10.1016/j.jacl.2018.03.077. Epub 2018 Mar 9.

PMID:
29627296
10.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.

Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122.

PMID:
29566128
11.

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.

Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE.

J Clin Lipidol. 2018 Mar - Apr;12(2):348-355.e2. doi: 10.1016/j.jacl.2018.01.002. Epub 2018 Jan 12.

12.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L.

J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. Review.

PMID:
29325642
13.
14.

Dietary quality and markers of inflammation: No association in youth with type 1 diabetes.

Liese AD, Ma X, Ma X, Mittleman MA, The NS, Standiford DA, Lawrence JM, Pihoker C, Marcovina SM, Mayer-Davis EJ, Puett RC.

J Diabetes Complications. 2018 Feb;32(2):179-184. doi: 10.1016/j.jdiacomp.2017.10.015. Epub 2017 Nov 6.

PMID:
29198994
15.

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.

Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2018 Feb;41(2):348-355. doi: 10.2337/dc17-1638. Epub 2017 Nov 28.

PMID:
29183908
16.

Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.

Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S.

J Clin Lipidol. 2018 Jan - Feb;12(1):122-129.e2. doi: 10.1016/j.jacl.2017.10.024. Epub 2017 Nov 2.

PMID:
29174389
17.

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.

Romagnuolo R, Scipione CA, Marcovina SM, Gemin M, Seidah NG, Boffa MB, Koschinsky ML.

PLoS One. 2017 Jul 27;12(7):e0180869. doi: 10.1371/journal.pone.0180869. eCollection 2017.

18.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, Roddy T, Johnson-Levonas AO, Gutstein DE, Marcovina SM, Rader DJ, Ginsberg HN, Millar JS, Reyes-Soffer G.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770-1775. doi: 10.1161/ATVBAHA.117.309549. Epub 2017 Jul 20.

19.

Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.

Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, Lader E, Rader DJ.

Pharmacogenet Genomics. 2017 Aug;27(8):285-293. doi: 10.1097/FPC.0000000000000289.

20.

Validity of Postmortem Glycated Hemoglobin to Determine Status of Diabetes Mellitus in Corneal Donors.

Soper MC, Marcovina SM, Hoover CK, Calhoun PM, McCoy KE, Stoeger CG, Schmidt GA, Arafah BM, Price MO, Szczotka-Flynn LB, Lass JH.

Cornea. 2017 Aug;36(8):942-947. doi: 10.1097/ICO.0000000000001211.

PMID:
28542087
21.

Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood.

Dabelea D, Stafford JM, Mayer-Davis EJ, D'Agostino R Jr, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH, Pop-Busui R, Saydah S, Hamman RF, Pihoker C; SEARCH for Diabetes in Youth Research Group.

JAMA. 2017 Feb 28;317(8):825-835. doi: 10.1001/jama.2017.0686.

22.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.

Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.

23.

Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.

Varga TV, Winters AH, Jablonski KA, Horton ES, Khare-Ranade P, Knowler WC, Marcovina SM, Renström F, Watson KE, Goldberg R, Florez JC, Pollin TI, Franks PW.

Circ Cardiovasc Genet. 2016 Dec;9(6):495-503. doi: 10.1161/CIRCGENETICS.116.001457. Epub 2016 Oct 26.

24.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
25.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

26.

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.

Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Paré G, Mannino GC, Buranasupkajorn P, Mendonca C, Hastings T, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2016 Nov;39(11):1915-1924. Epub 2016 Aug 15.

27.

Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.

Albers JJ, Slee A, Fleg JL, O'Brien KD, Marcovina SM.

Atherosclerosis. 2016 Aug;251:454-459. doi: 10.1016/j.atherosclerosis.2016.06.019. Epub 2016 Jun 11.

28.

Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Diffenderfer MR, Lamon-Fava S, Marcovina SM, Barrett PH, Lel J, Dolnikowski GG, Berglund L, Schaefer EJ.

Metabolism. 2016 Apr;65(4):381-90. doi: 10.1016/j.metabol.2015.10.031. Epub 2015 Nov 6.

29.

Association of adherence to a Mediterranean diet with glycemic control and cardiovascular risk factors in youth with type I diabetes: the SEARCH Nutrition Ancillary Study.

Zhong VW, Lamichhane AP, Crandell JL, Couch SC, Liese AD, The NS, Tzeel BA, Dabelea D, Lawrence JM, Marcovina SM, Kim G, Mayer-Davis EJ.

Eur J Clin Nutr. 2016 Jul;70(7):802-7. doi: 10.1038/ejcn.2016.8. Epub 2016 Feb 24.

30.

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.

Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61. doi: 10.1210/jc.2015-3754. Epub 2016 Feb 22.

31.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.

32.

Serum amyloid A impairs the antiinflammatory properties of HDL.

Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O'Brien KD, Marcovina SM, Wight TN, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A.

J Clin Invest. 2016 Feb;126(2):796. doi: 10.1172/JCI86401. Epub 2016 Feb 1. No abstract available.

33.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

34.

Serum amyloid A impairs the antiinflammatory properties of HDL.

Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O'Brien KD, Marcovina SM, Wight TN, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A.

J Clin Invest. 2016 Jan;126(1):266-81. doi: 10.1172/JCI83475. Epub 2015 Dec 7. Erratum in: J Clin Invest. 2016 Feb;126(2):796.

35.

Lipoprotein (a) measurements for clinical application.

Marcovina SM, Albers JJ.

J Lipid Res. 2016 Apr;57(4):526-37. doi: 10.1194/jlr.R061648. Epub 2015 Dec 4. Review.

36.

Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.

Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.

Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2686-93. doi: 10.1161/ATVBAHA.115.306136. Epub 2015 Oct 29.

PMID:
26515419
37.

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Scipione CA, Sayegh SE, Romagnuolo R, Tsimikas S, Marcovina SM, Boffa MB, Koschinsky ML.

J Lipid Res. 2015 Dec;56(12):2273-85. doi: 10.1194/jlr.M060210. Epub 2015 Oct 16.

38.

Biomarkers associated with severe hypoglycaemia and death in ACCORD.

Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER.

Diabet Med. 2016 Aug;33(8):1076-83. doi: 10.1111/dme.12883. Epub 2015 Sep 6.

39.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
40.

Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes.

Kim C, Christophi CA, Goldberg RB, Perreault L, Dabelea D, Marcovina SM, Pi-Sunyer X, Barrett-Connor E.

Diabet Med. 2016 Jan;33(1):32-8. doi: 10.1111/dme.12799. Epub 2015 May 29.

41.

Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.

Rao F, Schork AJ, Maihofer AX, Nievergelt CM, Marcovina SM, Miller ER, Witztum JL, O'Connor DT, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1704-11. doi: 10.1161/ATVBAHA.115.305306. Epub 2015 May 7.

42.

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML.

J Biol Chem. 2015 May 1;290(18):11649-62. doi: 10.1074/jbc.M114.611988. Epub 2015 Mar 16.

43.

Insulin sensitivity and arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study.

Shah AS, Black S, Wadwa RP, Schmiege SJ, Fino NF, Talton JW, D'Agostino R Jr, Hamman RF, Urbina EM, Dolan LM, Daniels SR, Marcovina SM, Dabelea D.

J Diabetes Complications. 2015 May-Jun;29(4):512-6. doi: 10.1016/j.jdiacomp.2015.02.004. Epub 2015 Feb 14.

44.

Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD.

Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER.

Diabetologia. 2015 Jun;58(6):1160-6. doi: 10.1007/s00125-015-3512-0. Epub 2015 Feb 5.

45.

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.

Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ; T1D Exchange Clinic Network.

Diabetes Care. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17.

PMID:
25519448
46.

The SEARCH for Diabetes in Youth study: rationale, findings, and future directions.

Hamman RF, Bell RA, Dabelea D, D'Agostino RB Jr, Dolan L, Imperatore G, Lawrence JM, Linder B, Marcovina SM, Mayer-Davis EJ, Pihoker C, Rodriguez BL, Saydah S; SEARCH for Diabetes in Youth Study Group.

Diabetes Care. 2014 Dec;37(12):3336-44. doi: 10.2337/dc14-0574. Review.

47.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

48.

Lipoprotein(a) metabolism.

Lamon-Fava S, Diffenderfer MR, Marcovina SM.

Curr Opin Lipidol. 2014 Jun;25(3):189-93. doi: 10.1097/MOL.0000000000000070. Review.

PMID:
24751932
49.

Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry.

Lassman ME, McLaughlin TM, Zhou H, Pan Y, Marcovina SM, Laterza O, Roddy TP.

Rapid Commun Mass Spectrom. 2014 May 30;28(10):1101-6. doi: 10.1002/rcm.6883.

PMID:
24711273
50.

Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease.

Williams PT, Zhao XQ, Marcovina SM, Otvos JD, Brown BG, Krauss RM.

Atherosclerosis. 2014 Apr;233(2):713-20. doi: 10.1016/j.atherosclerosis.2014.01.034. Epub 2014 Jan 30.

Supplemental Content

Loading ...
Support Center